Tandem Diabetes Care (TNDM) FY2020 results: revenue $499 million, up 37.7% on the year
Tandem Diabetes Care Inc. (TNDM) reported revenue of $499 million for fiscal 2020, the year ended 31 December 2020, up 37.7% on the year before. Net income was -$34 million, and diluted earnings per share $-0.56. The figures are the company's own, from the 10-K it filed with the SEC on 24 February 2021.
Revenue
$499 million
+37.7% on the year
FY2013FY2020
Operating margin
-1.6%
-4.6% a year earlier
FY2013FY2020
Net income
-$34 million
FY2013FY2020
Diluted EPS
-$0.56
FY2013FY2020
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Revenue
499
362
184
+37.7%
Cost of revenue
238
168
94.0
+41.8%
Gross profit
261
194
89.8
+34.1%
Gross margin
52.2%
53.6%
48.9%
Research and development
63.6
45.2
29.2
+40.7%
Selling, general and administrative
205
166
105
+23.6%
Operating income
-8.0
-16.7
-44.6
Operating margin
-1.6%
-4.6%
-24.3%
Pre-tax income
-36.3
-24.6
-123
Income tax
-1.9
0.1
0.1
Net income
-34.4
-24.8
-123
Net margin
-6.9%
-6.8%
-66.7%
Diluted EPS
-$0.56
-$0.42
-$2.55
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Operating cash flow
24.7
41.9
-8.3
-41.1%
Capital expenditure
27.4
19.5
3.0
+40.3%
Free cash flow
-2.7
22.4
-11.3
Free cash flow margin
-0.5%
6.2%
-6.1%
Cash from investing
-296
-57.0
-90.7
Cash from financing
314
24.2
117
+1,199.0%
Depreciation and amortisation
10.5
6.1
5.8
+72.1%
Share-based compensation
58.4
58.1
23.7
+0.6%
Diluted shares, weighted
61m
59m
n/a
+4.2%
Shares outstanding at period end
62m
59m
58m
+4.9%
Balance sheet
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Shareholders' equity
366
195
131
+87.9%
Debt
203
0.0
0.0
Operating lease liabilities
15.9
14.1
n/a
+13.2%
Other liabilities
131
117
75.0
+12.1%
Total liabilities and equity
716
326
206
+119.7%
Fixed assets
50.0
32.9
17.2
+51.9%
Investments
390
125
87.2
+211.6%
Cash and equivalents
94.6
51.2
41.8
+84.9%
Receivables
82.2
46.6
35.2
+76.4%
Inventory
63.7
49.1
19.9
+29.8%
Other assets
35.5
21.1
5.0
+68.7%
Total assets
716
326
206
+119.7%
10-K for the year ended 31 December 2020, filed 24 February 2021: the filing.